Literature DB >> 27034803

Genomic profiling of high-grade large-cell neuroendocrine carcinoma of the colon.

William A Hammond1, Jennifer A Crozier1, Raouf E Nakhleh1, Kabir Mody1.   

Abstract

High-grade neuroendocrine carcinoma (HGNEC) of the colon is a rare and aggressive cancer that has a poor prognosis. Currently no standard treatment exists, and published case series report an overall survival of approximately one year with treatment. Typically patients receive treatment similar to that recommended for small-cell lung cancer, extrapolating from the similarity in cancer biology. Here we report a case of HGNEC of the colon with genomic profiling that identified a KRAS G12D mutation and a PI3K mutation that has not yet been reported in the literature for this tumor type.

Entities:  

Keywords:  Colon cancer; genomic profiling; neuroendocrine carcinoma

Year:  2016        PMID： 27034803      PMCID： PMC4783747          DOI： 10.3978/j.issn.2078-6891.2015.090

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  18 in total

1.  A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.

Authors:  James D Smith; Diane L Reidy; Karyn A Goodman; Jinru Shia; Garrett M Nash
Journal:  Ann Surg Oncol       Date:  2014-04-24       Impact factor: 5.344

2.  Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.

Authors:  Nobuyuki Yamamoto; Junji Tsurutani; Naruo Yoshimura; Gyo Asai; Azusa Moriyama; Kazuhiko Nakagawa; Shinzo Kudoh; Minoru Takada; Yoshiaki Minato; Masahiro Fukuoka
Journal:  Anticancer Res       Date:  2006 Jan-Feb       Impact factor: 2.480

3.  The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.

Authors:  Jonathan R Strosberg; Domenico Coppola; David S Klimstra; Alexandria T Phan; Matthew H Kulke; Gregory A Wiseman; Larry K Kvols
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

4.  Consensus guidelines for the management and treatment of neuroendocrine tumors.

Authors:  Pamela L Kunz; Diane Reidy-Lagunes; Lowell B Anthony; Erin M Bertino; Kari Brendtro; Jennifer A Chan; Herbert Chen; Robert T Jensen; Michelle Kang Kim; David S Klimstra; Matthew H Kulke; Eric H Liu; David C Metz; Alexandria T Phan; Rebecca S Sippel; Jonathan R Strosberg; James C Yao
Journal:  Pancreas       Date:  2013-05       Impact factor: 3.327

5.  Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?

Authors:  Jinru Shia; Laura H Tang; Martin R Weiser; Baruch Brenner; N Volkan Adsay; Edward B Stelow; Leonard B Saltz; Jing Qin; Ron Landmann; Gregory D Leonard; Deepti Dhall; Larissa Temple; Jose G Guillem; Philip B Paty; David Kelsen; W Douglas Wong; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2008-05       Impact factor: 6.394

6.  A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).

Authors:  Kishan J Pandya; Suzanne Dahlberg; Manuel Hidalgo; Roger B Cohen; Martin W Lee; Joan H Schiller; David H Johnson
Journal:  J Thorac Oncol       Date:  2007-11       Impact factor: 15.609

7.  Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study.

Authors:  Irfan Cicin; Hakan Karagol; Sernaz Uzunoglu; Kazim Uygun; Ufuk Usta; Zafer Kocak; Murat Caloglu; Mert Saynak; Fusun Tokatli; Cem Uzal
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

8.  Neuroendocrine carcinomas of the colon and rectum.

Authors:  P E Bernick; D S Klimstra; J Shia; B Minsky; L Saltz; W Shi; H Thaler; J Guillem; P Paty; A M Cohen; W D Wong
Journal:  Dis Colon Rectum       Date:  2004-02       Impact factor: 4.585

9.  A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

Authors:  E F Smit; E Fokkema; B Biesma; H J Groen; W Snoek; P E Postmus
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

10.  Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.

Authors:  Shigeki Umemura; Sachiyo Mimaki; Hideki Makinoshima; Satoshi Tada; Genichiro Ishii; Hironobu Ohmatsu; Seiji Niho; Kiyotaka Yoh; Shingo Matsumoto; Akiko Takahashi; Masahiro Morise; Yuka Nakamura; Atsushi Ochiai; Kanji Nagai; Reika Iwakawa; Takashi Kohno; Jun Yokota; Yuichiro Ohe; Hiroyasu Esumi; Katsuya Tsuchihara; Koichi Goto
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609
View more
  2 in total

1.  EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.

Authors:  James Saller; Shabnam Seydafkan; Mohammad Shahid; Manoj Gadara; Mauro Cives; Steven A Eschrich; David Boulware; Jonathan R Strosberg; Nasir Aejaz; Domenico Coppola
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

2.  A rare presentation of an ACTH-producing high-grade large cell neuroendocrine carcinoma with Cushing's syndrome.

Authors:  Francis Essien; Christine Persaud; David Dado; Rina Eden; Joshua Tate; George Shahin
Journal:  Clin Case Rep       Date:  2021-12-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.